OSI Pharmaceuticals to Present at the JP Morgan Annual Healthcare Conf

    Business Editors/Health/Medical Writers
    JPMorgan Annual Healthcare Conference 2005

    MELVILLE, N.Y.--(BUSINESS WIRE)--Jan. 4, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced that Colin Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals will present at the 23rd Annual JP Morgan Healthcare Conference in San Francisco on Monday, January 10, 2005 at 7:00PM Eastern Time. Dr. Goddard will provide an overview on the Company's product portfolio and business developments.
    The presentation will be webcast live and may be accessed by visiting OSI's website at www.osip.com. A replay of the webcast will also be available on the Company's website until Friday, January 21, 2005.

    About OSI Pharmaceuticals

    OSI Pharmaceuticals is a leading biotechnology company primarily focused on the discovery, development, and commercialization of high-quality oncology products that both extend life and improve the quality of life for cancer patients worldwide. OSI has a balanced pipeline of oncology drug candidates that includes signal transduction inhibitors, apoptosis inducers, and a next-generation cytotoxic chemotherapy agent. Tarceva(TM), OSI's flagship product, is the first OSI drug discovered and developed by OSI to obtain FDA approval. OSI exclusively markets Novantrone(R) (mitoxantrone concentrate for injection) for the approved oncology indications and Gelclair(R) for the relief of pain associated with oral mucositis. OSI also established Prosidion Limited, a diabetes and obesity subsidiary based in the United Kingdom. For additional information about the company, please visit http://www.osip.com.

--30--RC/ny*

CONTACT: OSI Pharmaceuticals, Inc. Kathy Galante, 631-962-2000 or Burns McClellan Representing OSI Media: Kathy Nugent, Ph.D., 212-213-0006 or Investors: Jonathan M. Nugent, 212-213-0006

KEYWORD: CALIFORNIA NEW YORK INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY TRADESHOW CONFERENCE CALLS SOURCE: OSI Pharmaceuticals, Inc.

Copyright Business Wire 2005